PURPOSE: @entity1463 occurs in 20% of @entity1 with @entity2132 ( @entity2132 ) and can compromise mobility and quality of life. EXPERIMENTAL DESIGN: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of @entity2213 (200 mg daily) or rituximab (375 mg/m(2) i.v. weekly * 4 doses, repeatable after 3 months) for treatment of cutaneous @entity1463 diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in @entity272 or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrent @entity204 . Secondary endpoints included changes of B-cell profiles in blood ( @entity8410 levels and cellular subsets), @entity1 -reported outcomes, and histopathology between responders and nonresponders with each therapy. RESULTS: SCR was observed in 9 of 35 [26%; 95% confidence interval (CI); 13%-43%] @entity1 randomized to @entity2213 and 10 of 37 (27%; 95% CI, 14%-44%) randomized to rituximab. Six (17%; 95% CI, 7%-34%) @entity1 in the @entity2213 arm and 5 (14%; 95% CI, 5%-29%) in the rituximab arm had treatment success. Higher percentages of activated B cells ( @entity2731 (+)) were seen at enrollment in rituximab-treated @entity1 who had treatment success (P = 0.01), but not in @entity2213 -treated @entity1 . CONCLUSIONS: These results support the need for more effective therapies for cutaneous @entity1463 and suggest that activated B cells define a subgroup of @entity1 with cutaneous @entity1463 who are more likely to respond to rituximab. Clin Cancer Res; 22(2); 319-27.   2015 AACR.

A Randomized Phase II Crossover Study of XXXX or Rituximab for @entity1463 after Hematopoietic Cell Transplantation.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient'] @entity8410 :: ('10673', 'Gene') :: ['BAFF'] @entity2731 :: ('939', 'Gene') :: ['CD27'] @entity1463 :: ('MESH:D012598', 'Disease') :: ['sclerosis', 'Cutaneous sclerosis'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'chronic graft-versus-host disease'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin sclerosis'] @entity204 :: ('MESH:D003643', 'Disease') :: ['malignancy or death'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib']
@entity2213 :: (MESH:C097613,Chemical) :: ['Imatinib']
